*Updated 2017* Meet Clay Siegall, the Power behind Seattle Genetics Company (CEO)

UPDATE: March 22nd 2017: Seattle Genetics CEO Clay Siegall closes deal in Washington mansion! Learn more here: https://www.heraldnet.com/business/most-expensive-home-in-snohomish-county-takes-your-breath-away/

Wondering why Seattle Genetics Company has been doing so well? Clay B Siegal is behind all this success. Siegall is the CEO, the President and also the Chairman of the Board of management of the company. Seattle Genetics was started in 1998 by Clay Siegall among others. Clay is a trained scientist, and his firm normally specializes on scientific innovations as well as the desire to help patients. Clay has been an outstanding leader has been able to oversee the organization all along. Currently the company develops an antibody-drug conjugate that treats cancer.

Education and Milestones at Seattle Genetics Company
Clay has succeeded in pushing Seattle Genetics into some licenses particularly for technology like Roche, Pfizer, GlaxoSmithKline and AbbVie. He decided to detach the money-raising activities that secure millions of dollars through public and private financing. For example, he did it in the Initial Public Offer conducted in 2001. In 2014, Dr. Siegall joined the Ultragenyx as a member of the board of management. Before co-founding Seattle Genetics, Clay used to work for the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997. Clay also worked for the National Cancer Institute as well as the National Institute of Health from 1988 to 1991. Clay is a board member of the two private biotechnology companies, BioPharmaceuticals, and Mirna Therapeutics. Siegall also holds a BSc in Zoology from the University of Maryland. Later on, he graduated from George Washington University with a Ph.D. in Genetics.

Other Roles
Mirna Therapeutics named Clay Siegall as its outside board member in January 2013. Mirna was in dire need of his expansive experiences in the pharmaceutical sector, which will accelerate it in their journey in the modification and development of micro-RNA-based therapeutics. Clay views micro-RNA-based therapeutics as a critical field in conducting cancer research. He said that Mirna has employees who are very productive. He also admitted that he was very pleased to be named in the outside board of directors and he was ready to cooperate with other board members to modify its vital systems for patients. Besides the above achievements, Clay is also an accomplished author who holds 15 patents and has completed numerous publications.